What’s New with Innocoll?
Catch up on the latest developments.
Innocoll Holdings Ltd. Appoints Kimball Hall as Chief Executive Officer
Innocoll and DURECT Announce U.S. launch of POSIMIR®
Innocoll Announces Strategic Investment from Hillhouse Investment
Innocoll Announces Publication of Positive Results from Pivotal Clinical Trial of POSIMIR in Arthroscopic Subacromial Decompression
Innocoll Announces Positive Topline Results for XARACOLL® (bupivacaine hydrochloride) Implant in a Phase 3 Study to Support Expanded Use
Innocoll Announces Co-Promotion Agreement for Hernia Product Portfolio
Innocoll Announces Successful Completion of Debt Refinancing
DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)
Innocoll Biotherapeutics plc Announces First Patients In Phase 3 Clinical Trials for Label Expansion of Xaracoll® (bupivacaine hydrochloride) Implant
Anthony Galdi Appointed Chief Commercial Officer of Innocoll